 |
| Anno II | Numero 9 | Gennaio 2017 |
| Comitato scientifico editoriale: Massimo Di Maio, Silvia Novello Editore: Intermedia – Direttore Responsabile: Mauro Boldrini |
| Notizie dalla ricerca |
Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC) |
| Brain metastases (BM) are frequent in small cell lung cancer (SCLC). Novel insights into their pathobiology are needed for development of better therapies. We investigated tumor-infiltrating lymphocyte (TIL) subsets (CD3+, CD8+, CD45RO+, FOXP3+ and PD-1+) and expression of PD-L1 in a series of 32 SCLC BM specimens and four matched primary tumor specimens using immunohistochemistry. 30/32 (93.8 %) BM specimens showed TIL infiltration. CD3+ TILs were observed in … |
| Continua a leggere |
| Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies |
| Alternative predictive end points for overall survival (OS), such as tumor response and progression-free survival (PFS), are useful in the early detection of drug efficacy; however, they have not been fully investigated in patients with advanced NSCLC treated with anti-programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) antibodies. In a systematic review of the reported prospective clinical trials, data for response rate, median PFS, and median OS were … |
| Continua a leggere |
| Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach |
| Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or its ligand, PD-L1, have gained momentum in the treatment of non-small cell lung cancer (NSCLC). However, their prognostic significance remains controversial. The present study evaluated the expression of PD-L1 and PD-1 and their potential role in an Immunoscore, supplementing the TNM classification of NSCLC. Tissue microarrays constructed from tumor tissue samples from 2 cohorts of a total of … |
| Continua a leggere |
| Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy |
| Immune checkpoint therapies exhibit impressive efficacy in some patients with melanoma or lung cancer, but the lack of response in most cases presses the question of how general efficacy can be improved. In addressing this question, we generated a preclinical tumor model to study anti-PD-1 resistance by in vivo passaging of Kras-mutated, p53-deficient murine lung cancer cells (p53R172HΔg/+K-rasLA1/+) in a syngeneic host exposed to repetitive dosing with anti-mouse PD-1 antibodies. PDL1 … |
| Continua a leggere |
| Fading With Time of PD-L1 Immunoreactivity in Non-Small Cells Lung CancerTissues: A Methodological Study |
| Blockade of inhibitory immune checkpoints is currently arising as a potential immunologic option for tumor therapy. Inhibition of programmed cell death protein 1 and/or its specific ligand programmed death-ligand 1 (PD-L1) was effective in clinical trials in advanced melanoma, non-small cell lung cancer (NSCLC) bladder and kidney cancer. The predictive role of the immunohistochemical (IHC) expression of PD-L1 is highly debated. Different reagents, clones, cutoffs of cell expression and … |
| Continua a leggere |
| Appuntamenti AIOM |
Metodologia della Ricerca Clinica Corso teorico pratico: “Come si scrive un protocollo di ricerca clinica” |
| Negrar, 31 gennaio – 1 febbraio 2017 Iscrizioni entro il 20 gennaio |
| FONICAP Congresso Nord-Est Tumori polmonari e metastasi ossee: dalla ricerca alla pratica clinica |
| Preganziol (TV), 20 gennaio 2017 |
| Innovative Therapy, Monoclonal Antibodies and Beyond – 7th Edition |
| Milano, 27 gennaio 2017 |
| Revisioni Sistematiche e Meta-Analisi |
| Negrar, 10 – 11 febbraio 2017 Iscrizioni entro il 3 febbraio |
| SONDALO LUNG 16: New Light On Thoracic Tumors, Post Vienna 2016 |
| Tirano, 11 febbraio 2017 |
| Corso base di formazione in psiconcologia per psicologi e medici – XX Edizione |
| Milano, 20 – 23 febbraio 2017 (I modulo) Milano, 27 – 30 marzo 2017 (II modulo) |
| Studi Clinici: Metodologia A good foundation |
| Negrar (VR), 8 – 9 marzo 2017 |
| Studi Clinici: Criticità Interpretative Confidence, directness, relevance |
| Negrar (VR), 24 – 25 marzo 2017 |
| Immunoterapia nei Tumori del Polmone e dell’Urotelio A che punto siamo? |
| Roma, 27 – 28 marzo 2017 |
| Approccio multidisciplinare nel trattamento del microcitoma polmonare: tra tradizione e prospettive future |
| Roma, 31 marzo 2017 |
| Conferenza Nazionale CIPOMO La gestione del rischio in oncologia tra sicurezza e qualità |
| Ascoli Piceno, 31 marzo – 1 aprile 2017 |
| Questi e altri appuntamenti si possono consultare sul sito AIOM www.aiom.it |
| Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001 Per contattare la redazione e commentare le notizie clicca qui: redazione Per consultare i numeri arretrati della newsletter clicca qui: archivio Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI |
Questo progetto è stato realizzato con il contributo di  |